 | | Vol. 10.32 – 17 August, 2022 |
| |
|
|
| The authors presented data from a study in nonhuman primates demonstrating durable protection against the Omicron BA.1 variant induced by a subunit SARS-CoV-2 vaccine comprising the receptor binding domain of the ancestral strain on the I53-50 nanoparticle adjuvanted with AS03.
[Science Translational Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Immunizing a human VH1-2/Vκ1-33-rearranging mouse model with SARS-CoV-2 spike protein immunogens elicited several VH1-2/Vκ1-33-based neutralizing antibodies that bound receptor-binding-domain in a different mode from each other and from those of many prior human patient-derived VH1-2-based neutralizing antibodies.
[Science Immunology] |
|
|
|
| Researchers reported that vaccinated BALB/c mice did not recapitulate faithfully the breadth and potency of neutralizing antibody responses elicited by various vaccine platforms against variants of concern, as compared to non-human primates or humans, suggesting caution should be exercised when interpreting data obtained with this animal model.
[Cell Reports] |
|
|
|
| Scientists reported on the generation of hACE2.16, an anti-ACE2 antibody that recognized and blocked ACE2-RBD binding without affecting ACE2 enzymatic activity.
[iScience] |
|
|
|
| The authors described the cellular complexity of human alveolar and tracheobronchial air liquid interface tissue models during SARS-CoV-2 and influenza A virus infections.
[Communications Biology] |
|
|
|
| Investigators showed that, while Apilimod and other PIKfyve inhibitors had potent antiviral activity in various cell lines against multiple human coronaviruses, these compounds worsened disease in a COVID-19 murine model when given prophylactically or therapeutically.
[Communications Biology] |
|
|
|
| Scientists found that the expressions of both vacuolar-ATPase and calprotectin increased in SARS-CoV-2 infection, by analyzing single-cell RNA sequencing, bulk-RNA sequencing, and proteomics, respectively.
[Cell Death Discovery] |
|
|
|
| In this randomized, double-blinded, placebo-controlled Phase II/III trial, researchers evaluated the safety and efficacy of multi-dose Bacillus Calmette-Guerin (BCG) vaccine for prevention of COVID-19 and other infectious disease in a COVID-19-unvaccinated, at-risk-community-based cohort.
[Cell Reports Medicine] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists showed the development of long-acting injectable drug formulations of the anti-tuberculosis drug rifabutin made of biodegradable polymers and biocompatible solvents that solidified after subcutaneous injection.
[Nature Communications] |
|
|
|
| Investigators focused on the development of a universal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA platform.
[Nature Communications] |
|
|
|
| The authors demonstrated that AAV6.2FF-mediated expression of murine IgG2a Ebola virus (EBOV) monoclonal antibodies, 2G4 and 5D2, protected from mouse-adapted-EBOV infection with none of the surviving mice developing anti-VP40 antibodies above background.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Researchers investigated lactic acid bacteria strains having beneficial effects on the cognitive function of healthy young mice and elucidated underlying characteristics by carrying out nanopore sequencing-based genomics and metagenomics analysis.
[Scientific Reports] |
|
|
|
| The authors identified small molecule inhibitors targeting homoserine acetyl transferase from M. tuberculosis and demonstrated that conditional repression of metX resulted in inhibition of M. tuberculosis growth in vitro.
[Scientific Reports] |
|
|
|
|
| Scientists discuss strategies for the induction of potent and broad HIV-1 broadly neutralizing antibodies and outline the steps that may be necessary for ultimate success.
[Nature Reviews Immunology] |
|
|
|
| Investigators provide a concise review of the development and physiological role of CD8+ resident memory T cells, their involvement in diseases, and their potential therapeutic exploitation.
[Science Advances] |
|
|
|
| The authors focus on the use of virus-like particles for the development of vaccines with broad fields of indications ranging from classical vaccines against viruses to therapeutic vaccines against chronic inflammation, pain, allergy, and cancer.
[Cellular & Molecular Immunology] |
|
|
|
|
| Pfizer, Inc. and Valneva SE announced the initiation of a Phase III clinical study, Vaccine Against Lyme for Outdoor Recreationists, to investigate the efficacy, safety, and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
[Pfizer, Inc.] |
|
|
|
| A new animal virus that can infect people has been identified in eastern China. But scientists say they are not overly concerned because the virus doesn’t seem to spread easily between people, nor is it fatal.
[Nature News] |
|
|
|
| Six Weill Cornell Medicine postdoctoral associates, instructors and junior faculty seeking to pursue independent research careers have received 2022 JumpStart Career Development awards.
[Weill Cornell Medicine] |
|
|
|
|
| October 20 – 21, 2022
Turin, Italy |
|
|
|
|
|
| | Washington University in St. Louis – St. Louis, Missouri, United States |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | University of Alberta – Edmonton, Alberta, Canada |
|
|
|
| | University Hospital Cologne – Cologne, Germany |
|
|
|
| | Dalla Lana School of Public Health – Toronto, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
